Transom Real Estate Closes Inaugural Developer Fund, Expands Multifamily Pipeline Across New England

Transom Real Estate has announced the successful closing of its inaugural investment fund, marking a significant milestone in the firm’s growth as a vertically integrated multifamily developer across Greater New England. The fund will serve as a general-partner co-investment vehicle supporting Transom-led, ground-up multifamily developments, aligning long-term capital with disciplined project execution.

When combined with construction financing and limited-partner equity, Transom expects the fund to help deploy more than $650 million of total capital toward the development of much-needed multifamily housing in a region facing an acute housing shortage. The fund was privately placed through long-standing relationships and builds on Transom’s established track record of delivering design-forward, community-oriented residential projects throughout New England.

Notable recent developments include Zero Athens, Fox Howe Framingham, 212 Stuart Street, Bremen 282, and Northampton Residences, reflecting the firm’s ability to execute across urban infill, transit-oriented, and mixed-use environments. With a robust pipeline of carefully selected opportunities, Transom is positioned to deploy capital efficiently across multiple projects while addressing structural housing supply constraints.

Channel Point Capital Founding Partner Andrew Musto said “Transom’s success is rooted in its execution discipline and the strength of its network across New England’s development, capital, and municipal ecosystems. That combination enables the team to pursue projects others simply don’t see or can’t access.”

Earlier this year, Transom was also selected by the City of Medford to lead redevelopment of key parcels in Medford Square, further underscoring the firm’s growing presence in complex, community-shaping projects.


Previous
Previous

Venezia FC Advances Plans for New Stadium as Club’s Global Brand Momentum Continues

Next
Next

Cambrian Bio Raises $23M to Expand Longevity Therapeutics Platform